LEPU BIO-B: The results of the registrational clinical study of MRG003 will be presented in LBA format at the 2025 ASCO Annual Meeting
I'm PortAI, I can summarize articles.
LEPU BIO-B announced that the key registration clinical study results of its candidate drug MRG003 will be presented as a major research abstract at the 2025 ASCO Annual Meeting, along with an oral presentation. MRG003 is an innovative antibody-drug conjugate targeting recurrent or metastatic nasopharyngeal carcinoma
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments